Israël - anglais - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - vildagliptin - tablets - vildagliptin 50 mg - vildagliptin - vildagliptin s.k. is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose. as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. vildagliptin s.k. is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control. vildagliptin s.k. is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• in combination with a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - vildagliptin 50 mg - tablet - 50 mg - vildagliptin 50 mg - vildagliptin

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vildagliptin 50 mg - tablet - 50 mg - vildagliptin 50 mg - vildagliptin

Malte - anglais - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malte - anglais - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Malte - anglais - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - tablet - vildagliptin 50 mg - drugs used in diabetes

Union européenne - anglais - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Malte - anglais - Medicines Authority

genericon pharma gesellschaft m.b.h hafnerstrasse 211, 8054 graz, austria - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malte - anglais - Medicines Authority

genericon pharma gesellschaft m.b.h hafnerstrasse 211, 8054 graz, austria - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Australie - anglais - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - vildagliptin, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; magnesium stearate; lactose; microcrystalline cellulose - treatment of diabetes mellitus type 2 in persons 18 years of age and older, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes: - as monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. - in dual combination with one of metformin, a sulfonylurea or pioglitazone when diet, exercise and the single agent do not result in adequate glycaemic control. - in triple combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. - in combination with insulin (with or without metformin) when diet, exercise and a stable dose of insulin do not result in adequate glycaemic control.